Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions

Journal of the American College of Cardiology

Volumn 51, Issue 23, 2008, Pages 2220-2227

  Brar, Somjot S ^a   Kim, John ^b   Brar, Simerjeet K ^b   Zadegan, Ray ^b   Ree, Michael ^b   Liu, In Lu A ^b   Mansukhani, Prakash ^b   Aharonian, Vicken ^b   Hyett, Ric ^b   Shen, Albert Yuh Jer ^b,c  

^a NewYork Presbyterian Hospital   (United States)

^b Kaiser Permanente ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG USE; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVASCULARIZATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PROGRESSION; DRUG-ELUTING STENTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 44449141389     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.063     Document Type: Article

References (26)

1. Smith Jr. S.C., Faxon D., Cascio W., et al. Prevention conference VI: diabetes and cardiovascular disease: Writing Group VI: revascularization in diabetic patients. Circulation 105 (2002) e165-e169
2. Carrozza Jr. J.P., Kuntz R.E., Fishman R.F., and Baim D.S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 118 (1993) 344-349
3. Rozenman Y., Sapoznikov D., and Gotsman M.S. Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. Clin Cardiol 23 (2000) 890-894
4. Mathew V., Gersh B.J., Williams B.A., et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109 (2004) 476-480
5. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
6. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
7. Finn A.V., Palacios I.F., Kastrati A., and Gold H.K. Drug-eluting stents for diabetes mellitus: a rush to judgment?. J Am Coll Cardiol 45 (2005) 479-483
8. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
9. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
10. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
11. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
12. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
13. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
14. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
15. Pfisterer M., Brunner-La Rocca H.P., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
16. Patterson C., Mapera S., Li H.H., et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 26 (2006) 1473-1480
17. Farb A Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
18. Schwartz R.S., Chronos N.A., and Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44 (2004) 1373-1385
19. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
20. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
21. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
22. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
23. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
24. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
25. Wang P.S., Benner J.S., Glynn R.J., Winkelmayer W.C., Mogun H., and Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13 (2004) 11-19
26. West S.L., Savitz D.A., Koch G., Strom B.L., Guess H.A., and Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142 (1995) 1103-1112